Clinical trial
Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and…
NCT00366262 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00366262 |
|---|---|
| Title | Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen |
| Official title | A Randomized, Double-Blind, Parallel Group Study To Compare The 7-Day Gastrointestinal Safety of 2 Doses of PLA-695 To That Of Placebo And Naproxen |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | PLA-695, Naproxen, Placebo |
| Start date | Jun 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Aug 21, 2006 |
| Last update posted | Aug 5, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: